Results 131 to 140 of about 677,625 (318)

The placebo effect

open access: yes, 2018
“Placebo: a usually pharmacologically inert preparation prescribed more for the mental relief of the patient than for its actual effect on a disorder” – Merriam-Webster Medical Dictionary Everyone has heard of placebos, but have we ever wondered ...
Ismawi, Hidayatul Radziah
core  

Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion   +15 more
wiley   +1 more source

Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease

open access: yes
American Journal of Hematology, EarlyView.
Yoshito Nishimura   +4 more
wiley   +1 more source

Effect of Laser Posterior Nasal Neurolysis for the Treatment of Chronic Rhinitis: A Randomized Controlled Trial

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background To determine the safety and efficacy of laser ablation of the posterior nasal nerve (PNN) for the treatment of chronic rhinitis. Methods This study was a single‐center, prospective, single‐blinded, randomized sham‐controlled trial. Patients with a 24‐h reflective Total Nasal Symptom Score (rTNSS) ≧ 5, rhinorrhea ≧ 2, and congestion ≧
Jyun‐Yi Liao   +9 more
wiley   +1 more source

Lost and Found: Is Olfactory Recovery More Promising After COVID‐19 Than Other Causes, Even 2 Years Later?

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker   +6 more
wiley   +1 more source

Effect of Remifentanil on Intra-Ocular Pressure in Cataract Surgery under General Anesthesia with Isoflurane

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2009
BACKGROUND AND OBJECTIVE: One of the important aims in anesthetic management during ocular surgery is to provide adequate control of intraocular pressure (IOP) and increasing of this pressure would cause some dramatic complications even though visual ...
MR Ghodrati,   +3 more
doaj  

Placebo-controlled trial of misoprostol in cystic fibrosis

open access: yes, 1990
Placebo-controlled trial of misoprostol in cystic ...
P Robinson (12067037), PD Sly (14453628)
core  

Inflammatory Signatures Beyond Th1/Th2 Endotypes Provide Insights Into Postoperative Recurrence in Chronic Rhinosinusitis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel   +9 more
wiley   +1 more source

Biomimetic Nanoparticle Delivering Colchicine to Target Endothelial Inflammation for Atherosclerosis Treatment

open access: yesAdvanced NanoBiomed Research, EarlyView.
Platelet membrane‐coated layered double hydroxide nanoparticles were engineered to target inflamed endothelium at early‐stage atherosclerosis and enhance therapeutic efficacy. The biomimetic platform improves stability, immune escape, and inflamed vascular cell targeting, resulting in reduced oxidative stress and downregulated adhesion molecules.
Xiuwen Zhang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy